Roche, LumiraDx Deal Probed by U.K. Competition Watchdog
By Michael Susin The U.K. Competition and Markets Authority said it launched a merger inquiry regarding whether a deal for Roche Holding to buy certain companies linked to LumiraDx's point-of-care te
CMA Invites Views From Interested Parties On Roche, LumiraDx Deal
Express News | The UK Competition and Markets Authority begins investigation into Roche's acquisition of the LumiraDx platform
U.K. Competition Watchdog Weighs Potential Impact of Roche-LumiraDx
By Mauro Orru The U.K.'s Competition and Markets Authority is considering whether a deal for Roche Holding to buy certain companies linked to LumiraDx's point-of-care technology could stifle competit
News On LumiraDx Ltd. (LMDX) Now Under LMDXF
News On LumiraDx Ltd. (LMDX) Now Under LMDXF
12 Health Care Stocks Moving In Monday's After-Market Session
GainersSyra Health (NASDAQ:SYRA) shares rose 21.2% to $1.5 during Monday's after-market session. The market value of their outstanding shares is at $9.6 million. Universe Pharmaceuticals (NASDAQ:UPC)
U.S. Shares Higher at Close of Trade; Dow Jones Industrial Average up 0.58%
Top Midday Decliners
Solo Brands (DTC) said it appointed Christopher T. Metz as its new President and Chief Executive Officer, starting from Jan. 15, replacing John Merris. Shares slumped more than 36%, with intraday trad
US Stocks Mixed; Nasdaq Jumps Over 100 Points
U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around 100 points on Monday. Following the market opening Monday, the Dow traded down 0.45% to 37,296.85 while the NASDAQ rose
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersHarpoon Therapeutics (NASDAQ:HARP) stock increased by 110.9% to $22.25 during Monday's pre-market session. The company's market cap stands at $376.7 million. Ambrx Biopharma (NASDAQ:AMAM) stock
LumiraDx Announces Its Securities Will Be Suspended From Trading On Nasdaq At The Open Of Business On January 9th
LumiraDx Limited (NASDAQ:LMDX)(the "Company") today announced that it has received notification from The Nasdaq Stock Market LLC ("Nasdaq") that its securities will be suspended from trading at the op
LumiraDx Announces Its Securities Will Be Suspended From Trading on Nasdaq at the Open of Business on January 9th
LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX)(the "Company") today announced that it has received notification from The Nasdaq Stock Market LLC ("Nasdaq") that its securities will be
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersLongboard Pharmaceuticals (NASDAQ:LBPH) shares moved upwards by 200.7% to $18.13 during Tuesday's regular session. The company's market cap stands at $432.5 million. NGM Biopharmaceuticals (NAS
Roche (RHHBY) to Acquire LumiraDx's Point of Care Technology
Wall Street Set to Open 2024 Lower Amid Rise in Oil Prices, Ahead of Manufacturing, Construction Data
US stocks looked set to open lower in the first trading session of 2024 as oil prices climbed and investors looked ahead to monthly manufacturing and construction spending data. Dow Jones Industrial A
Roche Agrees To Purchase Part Of COVID-19 Test Player LumiraDx Diagnostics Platform For $295M
Friday, LumiraDx Limited (NASDAQ:LMDX) appointed joint administrators for two subsidiaries. The administrators signed a definitive agreement to sell certain companies of LumiraDx related to LumiraDx's
LumiraDx Falls on Agreement With Roche to Sell Assets
LumiraDx, Sacks Parente Golf And 3 Stocks To Watch Heading Into Tuesday
With U.S. stock futures trading mixed this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: Sacks Parente Golf, Inc. (NASDAQ:SPGC) announced the resignation o
Roche to Buy LumiraDx's Point of Care Technology Assets in Over $295 Million Deal
Roche (ROG.SW, RO.SW) signed a definitive agreement to buy a portion of the Nasdaq-listed LumiraDx group, comprising a range of immunoassay and clinical chemistry tests, for $295 million, according to a filing on Dec. 29, 2023.
Roche to Buy Part of LumiraDx Diagnostics Platform for $295 Million
No Data